Source: Myeloma – Hematology Advisor
Ciltacabtagene autoleucel had a favorable risk-benefit profile in a study of Chinese patients with relapsed/refractory multiple myeloma, according to researchers.
Read More
Recent Content
- Small intestinal angiodysplasia and hemorrhage associated with acquired von Willebrand syndrome type 2A secondary to multiple myeloma: Reversal after treatment with IRD regimen (a case report and a brief review of the literature)
- Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5
- EZH2 Promotes Multiple Myeloma Progression via STAT3 Pathway Activation
- A case report of biclonal immunoglobulin D lambda/lambda multiple myeloma in patient with liver echinococcosis
- Outcomes of percutaneous vertebroplasty in multiple myeloma: a tertiary neurosciences experience with long-term follow-up
- Dr Jagannath on the Potential Role for Linvoseltamab in R/R Multiple Myeloma
- Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma
- ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy
- Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1
- Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study